8-K: Kalaris Therapeutics Appoints New CFO, Chief Accounting Officer Departs

Kalaris Therapeutics, Inc. announced the appointment of Liisa Bayko as Chief Financial Officer and Treasurer, effective July 20, 2026, while Brett Hagen resigns as Chief Accounting Officer.

Summary

• Kalaris Therapeutics, Inc. has appointed Liisa Bayko as its new Chief Financial Officer and Treasurer, effective July 20, 2026.
• Ms. Bayko, age 55, brings extensive experience from her previous roles as Managing Director in Biotech Equity Research at Evercore ISI and JMP Securities.
• Brett Hagen has resigned as Senior Vice President, Finance and Chief Accounting Officer, with his resignation effective July 27, 2026.
• Amy Vandekop, the Company's Corporate Controller, has been appointed as the interim principal accounting officer, also effective July 27, 2026.
• Ms. Bayko's compensation includes an annual base salary of $475,000, a target bonus of up to 40% of her base salary, and an incentive stock option to purchase 220,000 shares.
• The employment agreement for Ms. Bayko outlines severance benefits in the event of termination by the Company without cause or by her for good reason, with enhanced benefits if occurring within a specified period around a change in control.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. While the appointment of a new CFO is significant, it is a routine executive change. The departure of the CAO introduces a minor element of uncertainty.

Positives

• Appointment of Liisa Bayko, an experienced finance professional with a strong background in biotech equity research, as CFO and Treasurer.
• Ms. Bayko's compensation package includes a competitive base salary and potential bonus, along with a significant stock option grant, aligning her incentives with the company's performance.
• The company has established clear severance provisions for Ms. Bayko, offering financial security in specific termination scenarios.

Negatives

• Resignation of Brett Hagen as Chief Accounting Officer, creating a leadership transition in a critical financial role.
• The interim appointment of Amy Vandekop as principal accounting officer may indicate a temporary solution while a permanent replacement is sought.

Risks

• Potential disruption or learning curve associated with the transition of key financial leadership roles.
• The effectiveness of the new CFO and interim principal accounting officer in navigating the company's financial strategy and reporting.
• Uncertainty regarding the reasons for Mr. Hagen's departure, which could signal underlying issues.

Future Outlook

The filing does not contain specific forward-looking financial guidance. However, the appointment of a new CFO with a strong background in equity research may signal a focus on financial strategy and investor relations.

Management Comments

• Ms. Bayko will serve as the Company's principal financial officer.
• Ms. Vandekop will serve as the Company's interim principal accounting officer.

Industry Context

StockSavvy.ai notes that executive transitions in finance, particularly the CFO role, are common in the biotechnology sector as companies mature or navigate funding rounds and clinical trial progress. The appointment of an experienced equity research professional like Ms. Bayko suggests a strategic focus on financial communication and market perception.

Management Changes

Stakeholder Impact

• Shareholders: The appointment of a new CFO may influence investor confidence and the company's financial communication strategy.
• Employees: The executive changes may lead to adjustments in financial department operations and reporting structures.
• Creditors: Stability in financial leadership is generally viewed positively by creditors.

Next Steps

• Ms. Bayko to assume duties as CFO and Treasurer on July 20, 2026.
• Ms. Vandekop to assume duties as interim principal accounting officer on July 27, 2026.
• The company will likely focus on integrating Ms. Bayko into the financial leadership team and ensuring a smooth handover of responsibilities.

Key Dates

Keywords

Kalaris Therapeutics, CFO Appointment, Chief Financial Officer, Chief Accounting Officer, Brett Hagen, Liisa Bayko, Amy Vandekop, Form 8-K